Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solid BiosciencesSLDB +2.26%34 EBIT per Share is $-1.93 as of Jun. 2026. GuruFocus rates SLDB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,168 Biotechnology companies, Solid Biosciences ranks better than 82.19% on this metric.
Solid Biosciences's EBIT per Share for the
three
months ended in Jun. 2026 was $-0.38.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.93.
During the past 3 years, the average EBIT per Share Growth Rate was 44.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 38.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 16.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Solid Biosciences's EBIT per Share or its related term are showing as below:
SLDB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -88.2 Med: 32.65 Max: 44
Current: 44
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Solid Biosciences was 44.00% per year. The lowest was -88.20% per year. And the median was 32.65% per year.
SLDB's 3-Year EBIT Growth Rate is ranked better than 82.19% of 1168
companies
in the Biotechnology industry
Industry Median: 15.45
vs SLDB: 44.00
Solid Biosciences (NAS:SLDB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Solid Biosciences EBIT per Share Related Terms
Solid Biosciences EBIT per Share Historical Data
* Premium members only.
The historical data trend for Solid Biosciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.93
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solid Biosciences (SLDB) has a EBIT per Share of $-1.93 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Solid Biosciences and its competitors. According to the industry distribution chart, Solid Biosciences ranks #208 out of 1168 companies in the Biotechnology industry, placing it in the top 17.8%.
Is Solid Biosciences' EBIT per Share too high?
Solid Biosciences' current EBIT per Share is $-1.93. Based on the distribution chart, Solid Biosciences ranks #208 out of 1168 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Solid Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Solid Biosciences' EBIT per Share compare to MNPR and DSGN?
According to the Biotechnology industry distribution chart, Solid Biosciences ranks #208 out of 1168 companies for EBIT per Share. This places Solid Biosciences in the top 18% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.45, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Solid Biosciences and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solid Biosciences's current EBIT per Share is $-1.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solid Biosciences stock overvalued right now?
Solid Biosciences (SLDB) has a current EBIT per Share of $-1.93. The current EBIT per Share is $-1.93. Solid Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Solid Biosciences (SLDB), the current EBIT per Share is $-1.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
34GF Score
Get the complete analysis for SLDB
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLDB has been successfully added to your 
